Humoral responses and immune protection in mice immunized with irradiated T. gondii tachyzoites and challenged with three genetically distinct strains of T. gondii

Immunology Letters

Volumn 138, Issue 2, 2011, Pages 187-196

  Zorgi, Nahiara Esteves ^a   Costa, Andrea ^a   Galisteo, Andrés Jimenez ^a   do Nascimento, Nanci ^b   De Andrade, Heitor Franco ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Bone marrow; High affinity antibodies; Immunologic memory; Ionizing radiation; Spleen; Toxoplasma gondii

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PROTOZOAL VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CONTROLLED STUDY; HUMORAL IMMUNITY; INFECTION PREVENTION; INFECTION RESISTANCE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; BONE MARROW CELLS; COBALT; GAMMA RAYS; HUMANS; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INJECTIONS, INTRAVENOUS; LIFE CYCLE STAGES; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROTOZOAN VACCINES; SPLEEN; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, ATTENUATED;

EID: 79959548703     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.04.007     Document Type: Article

References (50)

1. Dubey J.P., Lindsay D.S., Speer C.A. Structure of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and developmentof tissue cysts. Clin Microbiol Rev 1998, 11(2):267-299.
2. Derouin F., Pelloux H. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008, 14(12):1089-1101.
3. Petersen E. Toxoplasmosis. Semin Fetal Neonal Med 2007, 12(3):214-223.
4. Dubey J.F. Status of toxoplasmosis in sheep and goats in the United States. J Am Vet Med Assoc 1990, 196(2):259-262.
5. Kijlstra A., Jongert E. Control of the risk of human toxoplasmosis transmitted by meat. Int J Parasitol 2008, 38(12):1359-1370.
6. Parker S.J., Roberts C.W., Alexander J. CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol 1991, 84(2):207-212.
7. Yamamoto J.H., Vallochi A.L., Silveira C., Filho J.K., Nussenblatt R.B., Cunha-Neto E., et al. Discrimination between patients with acquired toxoplasmosis and congenital toxoplasmosis on the basis of the immune response to parasite antigens. J Infect Dis 2000, 181(June (6)):2018-2022.
8. Carvalho F.R., Silva D.A., Cunha-Júnior J.P., Souza M.A., Oliveira T.C., Béla S.R., et al. Reverse enzyme-linked immunosorbent assay using monoclonal antibodies against SAG1-related sequence, SAG2A, and p97 antigens from Toxoplasma gondii to detect specific immunoglobulin G (IgG), IgM, and IgA antibodies in human sera. Clin Vaccine Immunol 2008, 15(August (8)):1265-1271.
9. Jongert E., Roberts C.W., Gargano N., Förster-Wald E., Petersen E. Vaccines against Toxoplasma gondii: challenges and opportunities. Mem Inst Oswaldo Cruz 2009, 104(March (2)):252-266.
10. Buxton D., Innes E.A. A commercial vaccine for ovine toxoplasmosis. Parasitology 1995, 110(s1):S11-S16.
11. Sayles P.C., Johnson L.L. Intact immune defenses are required for mice to resist the ts-4 vaccine strain of Toxoplasma gondii. Infect Immun 1996, 64(8):3088-3092.
12. Fox B.A., Bzik D.J. Avirulent uracil auxotrophs based on disruption of orotidine-5'-monophosphate decarboxylase elicit protective immunity to Toxoplasma gondii. Infect Immun 2010, 78(9):3744-3752.
13. Wales A., Kusel J.R. Biochemistry of irradiated parasite vaccines: suggested models for their mode of action. Parasitol Today 1992, 8(11):358-363.
14. Hoffman S.L., Doolan D.L. Malaria vaccines-targeting infected hepatocytes. Nat Med 2000, 6(11):1218-1219.
15. Hiramoto R.M., Galisteo A.J., Do Nascimento N., Andrade H.F. 200Gy sterilized Toxoplasma gondii tachyzoites maintain metabolic functions and mammalian cell invasion, eliciting cellular immunity and cytokine response similar to natural infection in mice. Vaccine 2002, 20(16):2072-2081.
16. Wastling I.M., Harkins D., Buxton D. Western blot analysis of the IgG response of sheep vaccinated with S48 Toxoplasma gondii (Toxovax). Res Vet Sci 1994, 57(3):384-386.
17. Dlugonska H. Toxoplasma rhoptries: unique secretory organelles and source of promising vaccine proteins for immunoprevention of toxoplasmosis. J Biomed Biotechnol 2008, 2008:632424.
18. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47(August (3)):401-409.
19. Tangye S.G., Tarlinton D.M. Memory B cells: effectors of long-lived immune responses. Eur J Immunol 2009, 39(August (8)):2065-2075.
20. Cariappa A., Mazo I.B., Chase C., Shi H.N., Liu H., Li Q., et al. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. Immunity 2005, 23(October (4)):397-407.
21. Pillai S., Cariappa A. The bone marrow perisinusoidal niche for recirculating B cells and the positive selection of bone marrow-derived B lymphocytes. Immunol Cell Biol 2009, 87(January (1)):16-19.
22. Tumanov A.V., Grivennikov S.I., Kruglov A.A., Shebzukhov Y.V., Koroleva E.P., Piao Y., et al. Cellular source and molecular form of TNF specify its distinct functions in organization of secondary lymphoid organs. Blood 2010, 116(Nov (4)):3456-3464.
23. Mamani-Matsuda M., Cosma A., Weller S., Faili A., Staib C., Garçon L., et al. The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood 2008, 111(May (9)):4653-4659.
24. Amanna I.J., Slifka M.K. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010, July (236):125-138.
25. Lappalainen M., Hedman K. Serodiagnosis of toxoplasmosis. The impact of measurement of IgG avidity. Ann Ist Super Sanita 2004, 40(1):81-88.
26. Oliveira E.B., Ferra M.L.G., Perez R.M., Silva A.E.B., Lanzoni V.P., Granato C.F. In vitro-induced antibody production in chronic hepatitis C virus infection. Braz J Med Biol Res 2003, 36(3):361-368.
27. Letscher-Bru V., Pfaff A.W., bou-Bacar A., Filisetti D., Antoni E., Villard O., et al. Vaccination with Toxoplasma gondii SAG-1 protein is protective against congenital toxoplasmosis in BALB/c mice but not in CBA/J mice. Infect Immun 2003, 71(November (11)):6615-6619.
28. Igarashi M., Kano F., Tamekuni K., Machado R.Z., Navarro I.T., Vidotto O., et al. Toxoplasma gondii: evaluation of an intranasal vaccine using recombinant proteins against brain cyst formation in BALB/c mice. Exp Parasitol 2008, 118(3):386-392.
29. Jongert E., Verhelst D., Abady M., Petersen E., Gargano N. Protective Th1 immune responses against chronic toxoplasmosis induced by a protein-protein vaccine combination but not by its DNA-protein counterpart. Vaccine 2008, 26(41):5289-5295.
30. Golkar M., Shokrgozar M.A., Rafati S., Musset K., Assmar M., Sadaie R., et al. Evaluation of protective effect of recombinant dense granule antigens GRA2 and GRA6 formulated in monophosphoryl lipid A (MPL) adjuvant against Toxoplasma chronic infection in mice. Vaccine 2007, 25(May (21)):4301-4311.
31. Brink R., Phan T.G., Paus D., Chan T.D. Visualizing the effects of antigen affinity on T-dependent B-cell differentiation. Immunol Cell Biol 2008, 86(January (1)):31-39.
32. Buzoni-Gatel D., Schulthess J., Menard L.C., Kasper L.H. Mucosal defences against orally acquired protozoan parasites, emphasis on Toxoplasma gondii infections. Cell Microbiol 2006, 8(4):535-544.
33. Mack D.G., McLeod R. Human Toxoplasma gondii-specific secretory immunoglobulin A reduces T. gondii infection of enterocytes in vitro. J Clin Invest 1992, 90(December (6)):2585-2592.
34. Reed S.G., Bertholet S., Coler R.N., Friede M. New horizons in adjuvants for vaccine development. Trends Immunol 2009, 30(January (1)):23-32.
35. Debard N., Buzoni-Gatel D., Bout D. Intranasal immunization with SAG1 protein of Toxoplasma gondii in association with cholera toxin dramatically reduces development of cerebral cysts after oral infection. Infect Immun 1996, 64(June (6)):2158-2166.
36. Bonenfant C., Dimier-Poisson I., Velge-Roussel F., Buzoni-Gatel D., Del Giudice G., Rappuoli R., et al. Intranasal immunization with SAG1 and nontoxic mutant heat-labile enterotoxins protects mice against Toxoplasma gondii. Infect Immun 2001, 69(March (3)):1605-1612.
37. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001, 69(February (2)):1151-1159.
38. Cariappa A., Chase C., Liu H., Russell P., Pillai S. Naive recirculating B cells mature simultaneously in the spleen and bone marrow. Blood 2007, 109(March (6)):2339-2345.
39. Dziadek B., Gatkowska J., Brzostek A., Dziadek J., Dzitko K., Dlugonska H. Toxoplasma gondii: the immunogenic and protective efficacy of recombinant ROP2 and ROP4 rhoptry proteins in murine experimental toxoplasmosis. Exp Parasitol 2009, 123(September (1)):81-89.
40. Pena H.F., Gennari S.M., Dubey J.P., Su C. Population structure and mouse-virulence of Toxoplasma gondii in Brazil. Int J Parasitol 2008, 38(April (5)):561-569.
41. Williams D.M., Grumet F.C., Remington J.S. Genetic control of murine resistance to Toxoplasma gondii. Infect Immun 1978, 19(February (2)):416-420.
42. Fux B., Rodrigues C.V., Portela R.W., Silva N.M., Su C., Sibley D., et al. Role of cytokines and major histocompatibility complex restriction in mouse resistance to infection with a natural recombinant strain (type I-III) of Toxoplasma gondii. Infect Immun 2003, 71(November (11)):6392-6401.
43. Stanley A.C., Buxton D., Innes E.A., Huntley J.F. Intranasal immunisation with Toxoplasma gondii tachyzoite antigen encapsulated into PLG microspheres induces humoral and cell-mediated immunity in sheep. Vaccine 2004, 22(29-30):3929-3941.
44. Cerutti A., Immunology IgA changes the rules of memory. Science 2010, 328(June (5986)):1646-1647.
45. Ogra P.L., Karzon D.T. Distribution of poliovirus antibody in serum, nasopharynx and alimentary tract following segmental immunization of lower alimentary tract with poliovaccine. J Immunol 1969, 102:1423-1430.
46. Matson D.O., O'Ryan M.L., Herrera I., Pickering L.K., Estes M.K. Fecal antibody responses to symptomatic and asymptomatic rotavirus infections. J Infect Dis 1993, 167:577-583.
47. Ennis F.A., Yi-Hua Q., Schild G.C. Antibody and cytotoxic T lymphocyte responses of humans to live and inactivated influenza vaccines. J Gen Virol 1982, 58:273-281.
48. Sayles P.C., Gibson G.W., Johnson L.L. B cells are essential for vaccination-induced resistance to virulent Toxoplasma gondii. Infect Immun 2000, 68(March (3)):1026-1033.
49. Dubey J.P. Toxoplasmosis - a waterborne zoonosis. Vet Parasitol 2004, 126(December (1-2)):57-72.
50. Mackowiak M., Maki J., Motes-Kreimeyer L., Harbin T., Van Kampen K. Vaccination of wildlife against rabies: successful use of a vectored vaccine obtained by recombinant technology. Adv Vet Med 1999, 41:571-583.